# Long-Term Follow-up Study for Patients Previously Treated With JCAR015

> **NCT02813252** · — · COMPLETED · sponsor: **Juno Therapeutics, a Subsidiary of Celgene** · enrollment: 15 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **GENETIC:** JCAR015

## Key facts

- **NCT ID:** NCT02813252
- **Lead sponsor:** Juno Therapeutics, a Subsidiary of Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-30
- **Primary completion:** 2021-10-22
- **Final completion:** 2021-10-22
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02813252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02813252, "Long-Term Follow-up Study for Patients Previously Treated With JCAR015". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02813252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*